Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt N/A
SGEN's Cash to Debt is ranked higher than
59% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. SGEN: N/A )
Ranked among companies with meaningful Cash to Debt only.
SGEN' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Equity to Asset 0.76
SGEN's Equity to Asset is ranked higher than
61% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGEN: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
SGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.76 Max: 0.97
Current: 0.76
0.36
0.97
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
98% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGEN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 27.18
M-Score: 1.18
WACC vs ROIC
21.88%
-81.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -34.13
SGEN's Operating margin (%) is ranked higher than
60% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. SGEN: -34.13 )
Ranked among companies with meaningful Operating margin (%) only.
SGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -260.49  Med: -49.69 Max: -23.35
Current: -34.13
-260.49
-23.35
Net-margin (%) -33.51
SGEN's Net-margin (%) is ranked higher than
59% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. SGEN: -33.51 )
Ranked among companies with meaningful Net-margin (%) only.
SGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -242.65  Med: -48.72 Max: -23.22
Current: -33.51
-242.65
-23.22
ROE (%) -21.01
SGEN's ROE (%) is ranked higher than
61% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. SGEN: -21.01 )
Ranked among companies with meaningful ROE (%) only.
SGEN' s ROE (%) Range Over the Past 10 Years
Min: -128.57  Med: -35.29 Max: -21.01
Current: -21.01
-128.57
-21.01
ROA (%) -16.19
SGEN's ROA (%) is ranked higher than
62% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. SGEN: -16.19 )
Ranked among companies with meaningful ROA (%) only.
SGEN' s ROA (%) Range Over the Past 10 Years
Min: -50.86  Med: -18.13 Max: -12
Current: -16.19
-50.86
-12
ROC (Joel Greenblatt) (%) -242.32
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. SGEN: -242.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -903.49  Med: -564.59 Max: -178.02
Current: -242.32
-903.49
-178.02
Revenue Growth (3Y)(%) 10.30
SGEN's Revenue Growth (3Y)(%) is ranked higher than
61% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. SGEN: 10.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.7  Med: 35.05 Max: 148.1
Current: 10.3
7.7
148.1
EBITDA Growth (3Y)(%) 31.50
SGEN's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SGEN: 31.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: 2.5 Max: 31.5
Current: 31.5
-30.1
31.5
EPS Growth (3Y)(%) 25.20
SGEN's EPS Growth (3Y)(%) is ranked higher than
79% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. SGEN: 25.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34  Med: -1.3 Max: 27.9
Current: 25.2
-34
27.9
GuruFocus has detected 6 Warning Signs with Seattle Genetics Inc $SGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SGEN Guru Trades in Q1 2016

Columbia Wanger 1,763,796 sh (+8.81%)
PRIMECAP Management 13,589,187 sh (+5.49%)
Manning & Napier Advisors, Inc 289,140 sh (-19.18%)
» More
Q2 2016

SGEN Guru Trades in Q2 2016

Joel Greenblatt 30,082 sh (New)
George Soros 14,700 sh (New)
PRIMECAP Management 13,514,712 sh (-0.55%)
Columbia Wanger 1,428,393 sh (-19.02%)
Manning & Napier Advisors, Inc 228,321 sh (-21.03%)
» More
Q3 2016

SGEN Guru Trades in Q3 2016

Paul Tudor Jones 8,729 sh (New)
Manning & Napier Advisors, Inc 257,580 sh (+12.81%)
PRIMECAP Management 13,420,237 sh (-0.70%)
Columbia Wanger 682,974 sh (-52.19%)
George Soros 4,347 sh (-70.43%)
Joel Greenblatt 8,242 sh (-72.60%)
» More
Q4 2016

SGEN Guru Trades in Q4 2016

Ray Dalio 163,107 sh (New)
Jim Simons 253,313 sh (New)
Joel Greenblatt 12,900 sh (+56.52%)
Columbia Wanger 760,744 sh (+11.39%)
Paul Tudor Jones Sold Out
George Soros Sold Out
PRIMECAP Management 13,230,162 sh (-1.42%)
Manning & Napier Advisors, Inc 140,670 sh (-45.39%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:TSRO, NAS:ALKS, NAS:JAZZ, NAS:UTHR, OTCPK:NVZMY, NAS:EXEL, OTCPK:GMXAY, NAS:IONS, OTCPK:UCBJY, NAS:ACAD, NAS:ARIA, NAS:TECH, OTCPK:GIKLY, NAS:ALNY, NAS:GLPG, NAS:ICPT, NAS:RARE, NAS:BMRN, NAS:CBPO, NAS:CLVS » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc is a biotechnology company. It develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.

Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Its marketed product ADCETRIS, or brentuximab vedotin, is approved by the United States Food and Drug Administration, or FDA, for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is commercially available in more than 60 countries around the world, including in the United States, Canada, members of the European Union and Japan. It is collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Seattle Genetics retains commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda has commercial rights in the rest of the world. In addition to ADCETRIS and SGN-CD33A, its clinical-stage pipeline includes five other antibody-drug conjugate, or ADC, programs consisting of SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and an immuno-oncology agent called SEA-CD40, which is based on our sugar-engineered antibody, or SEA, technology. It sells ADCETRIS through a limited number of pharmaceutical distributors.. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.

Ratios

vs
industry
vs
history
P/B 14.41
SGEN's P/B is ranked lower than
91% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. SGEN: 14.41 )
Ranked among companies with meaningful P/B only.
SGEN' s P/B Range Over the Past 10 Years
Min: 1.88  Med: 9.27 Max: 35.99
Current: 14.41
1.88
35.99
P/S 21.72
SGEN's P/S is ranked lower than
61% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. SGEN: 21.72 )
Ranked among companies with meaningful P/S only.
SGEN' s P/S Range Over the Past 10 Years
Min: 9.87  Med: 18.95 Max: 45.24
Current: 21.72
9.87
45.24
Days Inventory 525.89
SGEN's Days Inventory is ranked lower than
95% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SGEN: 525.89 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s Days Inventory Range Over the Past 10 Years
Min: 245.66  Med: 522.11 Max: 639.76
Current: 525.89
245.66
639.76
Days Sales Outstanding 56.84
SGEN's Days Sales Outstanding is ranked higher than
54% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. SGEN: 56.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40  Med: 65.48 Max: 562.77
Current: 56.84
40
562.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.90
SGEN's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SGEN: -4.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -113.5  Med: -12.05 Max: -2.2
Current: -4.9
-113.5
-2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.42
SGEN's Price/Tangible Book is ranked lower than
88% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. SGEN: 14.42 )
Ranked among companies with meaningful Price/Tangible Book only.
SGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.04  Med: 9.02 Max: 21.61
Current: 14.42
2.04
21.61
Price/Median PS Value 1.15
SGEN's Price/Median PS Value is ranked lower than
64% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. SGEN: 1.15 )
Ranked among companies with meaningful Price/Median PS Value only.
SGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.68  Med: 1.05 Max: 30
Current: 1.15
0.68
30
Earnings Yield (Greenblatt) (%) -1.53
SGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. SGEN: -1.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.02  Med: 0 Max: 0
Current: -1.53
-4.02
0

More Statistics

Revenue (TTM) (Mil) $418.1
EPS (TTM) $ -1.00
Beta2.59
Short Percentage of Float17.12%
52-Week Range $28.32 - 75.36
Shares Outstanding (Mil)141.55

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 462 624 953
EPS ($) -1.12 -0.49 0.94
EPS w/o NRI ($) -1.12 -0.49 0.94
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
7 Stocks That Are Beating the Market Feb 21 2017 
Insiders Buy Herbalife, Sell MasterCard Nov 05 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 

More From Other Websites
SGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle... Feb 22 2017
SGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class... Feb 22 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Feb 22 2017
SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report Feb 21 2017
7 Stocks That Are Beating the Market Feb 21 2017
Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated... Feb 17 2017
VenBio Tries to Block Immunomedics Cancer Deal Feb 17 2017
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle... Feb 17 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of Commencement... Feb 17 2017
SEATTLE GENETICS INC /WA Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Feb 16 2017
SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle... Feb 15 2017
SGEN NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class... Feb 15 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Feb 15 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Feb 15 2017
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data Feb 15 2017
Seattle Genetics signs $2B licensing deal with Immunomedics for cancer drug Feb 14 2017
SGEN SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle... Feb 14 2017
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And... Feb 14 2017
Activist Investor to Block Partnership of Immunomedics and Seattle Genetics Feb 14 2017
Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017 Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)